| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.4 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.041 | 0.4 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | 0.053 | 0.4 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |